šŸŽ™ļø Gravitational Pull

[5 minutes to read] Plus: A new twist on the 401(k)

In partnership with

By Matthew Gutierrez and Shawn Oā€™Malley

Buy us a coffee ā˜•ļø

šŸ˜®ā€šŸ’ØĀ The S&P 500 is taking a chill pill.

Weā€™re amid the first 5% dip of the year, thanks largely to worries over global tensions and stubborn inflation numbers.

But let's not forget that the S&P shot up ~28% in just half a year from October to March. Investors are taking a breather, as they normally do: 5% pullbacks happen about four times yearly, even in good times.

They're so common that since 1900, the market has spent more than half its time in 5% dips.

But hey, rally resumed? Maybe. Stocks rose Wednesday, then dropped, after Federal Reserve Chair Jerome Powell (mostly) ruled out that the central bankā€™s next move could be a hike.

ā€” Matthew & Shawn

Hereā€™s todayā€™s rundown:

Today, we'll discuss the biggest stories in markets:

  • Ozempic gobbles up a whole economy

  • A new twist on the 401(k)

This, and more, in just 5 minutes to read.

POP QUIZ

In what year was the 401(k) plan introduced in the United States? (Scroll to the bottom to find out!)

Chart of the Day

Together With Value Investor Daily

Steal our best value stock ideas.

PayPal, Disney, and Nike all dropped 50-80% recently from all-time highs.

Are they undervalued? Can they turn around? Whatā€™s next? You donā€™t have time to track every stock, but should you be forced to miss all the best opportunities?

Thatā€™s why we scour hundreds of value stock ideas for you. Whenever we find something interesting, we send it straight to your inbox.

Subscribe free to Value Investor Daily with one click so you never miss out on our research again.

*Sponsored content

In The News

šŸ’Š The Ozempic Effect: Gobbling Up An Entire Economy

Made Using DALL-E

Novo Nordisk isnā€™t merely a pharmaceutical giant ā€” the maker of Ozempic and Wegovy is now Europeā€™s most valuable company. And lately, its home country, Denmark, has been hooked on that success.

A new Bloomberg story explores its impact on Europe through its groundbreaking drugs Ozempic and Wegovy. The medications that target diabetes and obesity have become global phenomena, attracting widespread attention from consumers, investors, and policymakers.

Gravitational pull: Novo Nordisk has become Europe's most valuable company (over $570 billion). The countryā€™s economy grew 1.9% last year, among the fastest in Europe, and almost all thanks to the pharmaceutical industry, led by Novo.

  • Novoā€™s rise has transformed Denmark's economy; its market capitalization has exceeded its GDP. Its philanthropic foundation rivals the Gates Foundation in assets, and its tax contributions have boosted government spending, particularly in areas such as defense, environmental initiatives, and support for Ukraine.

  • Novoā€™s trickle-down effect is enormous, even down to local flower shops, which have been ā€œexceptionally busy preparing welcome bouquets for new Novo employees.ā€

  • Said the mayor of Kalundborg, Denmark: "Today, itā€™s known as Novo City."

  • Novo Nordisk's influence extends beyond economics, shaping educational priorities, research agendas, and political decisions.Ā 

There are also risks, both for the company and its home market. The company's strategic decisions can have far-reaching consequences, impacting everything from public finances to academic research and employment prospects for Danish graduates.Ā 

Source: Bloomberg

Why it matters:

Roughly two out of three U.S. adults are overweight or obese (69%), and about one out of three are obese. Thereā€™s a huge market here.Ā 

Diabetes and obesity drugs have ā€œwon over the rich and famous, generated billions in sales, and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030,ā€ Bloomberg reports.Ā 

Novo risk: Novo is a case study highlighting the potential pitfalls of over-reliance on a single company for economic growth. Although Novo's success has brought prosperity to Denmark, there are concerns about its sustainability and broader implications for Danish society.Ā 

  • Rising public spending on Novo's medications has sparked debates about healthcare costs and prompted the company to adjust its pricing strategies: This week, Novo Nordisk cut the price of Ozempic in Denmark by a third from $188 to $125. They charge Americans about $969.

  • Some warn that Novo could become a curse, pointing to how Finland endured a long recession after Nokia lost its footing in mobile phones with the arrival of the iPhone.

  • Nearly all of Novo Nordiskā€™s revenue is earned overseas, more than half in the United States alone. Itā€™s the largest corporate taxpayer in Denmark, paying 15% of the countryā€™s entire corporate tax intake last year.

  • Novo Nordisk's dominance presents opportunities for Denmark's pharmaceutical sector, but diversifying the country's economy and reducing dependency on a single industry player present challenges.Ā 

Read more (Bloomberg)

More Headlines

šŸŽ§ Inside Appleā€™s domination of the headphones business

šŸ¤‘Ā Americans were paid an additional $235 billion last year, thanks to Fed

šŸ—£ļø Warren Buffettā€™s youngest son discusses fatherā€™s legacyĀ 

šŸ’» How long it would take a hacker to brute force your password

šŸƒā€ā™€ļø Climbing stairs is associated with living longer, per new research

šŸ’°Gold pocket watch from ā€˜Titanicā€™ sells for $1.5 million

šŸ¤” BlackRockā€™s Plan for Your Retirement: A Monthly Check

Made Using DALL-E

Could the old-fashioned 401(k) be in for a facelift?

Hereā€™s a twist: 401(k) plans that offer employees retirement paychecks they can rely on for life.Ā 

BlackRock's CEO Larry Fink sees this option as becoming the default retirement investment strategy. Their ā€œLifePath Paycheck funds,ā€ incorporating annuities, aim to address the looming U.S. retirement crisis.

Avangrid and 13 other employers have adopted the funds as their default investment option for around 500,000 employees so far.Ā 

What to know: The funds resemble standard target-date retirement funds, adjusting asset allocation as retirement approaches.Ā 

  • However, they start investing in annuity contracts at age 55, comprising roughly 30% of the portfolio by age 65.

  • Employees between ages 59.5 and 72 can purchase an annuity, guaranteeing a lifelong paycheck, with the remaining 70% of the portfolio still invested in stocks and bonds or redeemable for cash.

  • BlackRock CEO Larry Fink says the new plan "will one day be the default retirement investment strategy,ā€ adding: ā€œEven people who know how to save for retirement still donā€™t know how to spend for it."

Source: The Wall Street Journal

Why it matters:

The future? Concerns about fees and complexity surround annuities within target-date funds. One analyst noted, "There are fees in the annuity spread that you canā€™t see. That opaqueness opens itself up to the chance of litigation risk."

  • Proponents argue they simplify retirement income planning without requiring financial advisors.Ā 

  • BlackRock's funds offer low fees, with an annual expense ratio starting at 0.1% and rising to 0.16% after age 55, compared to the industry average of 0.48% for target-date funds.

Source: WSJ

The industry's focus on such products is growing, driven by the increasing number of retirees among the Baby Boomer generation.Ā 

  • While BlackRock's offering has gained traction, Vanguard and Fidelity, the largest target-date fund providers, have yet to announce similar plans. Fink says that will change soon.

Together With Native Path*

Sciatica Sufferers Find Solace

Struggling with sciatica or nerve discomfort? Meet Native Balanceā€”a supplement that speaks directly to your body's needs with potent magnesium forms that target inflammation and promote nerve regeneration.

Embrace this opportunity for relief at an exceptional valueā€”62% off retail price plus free shipping while supplies last.

Quick Poll

Would you consider opting for a 401(k) plan with embedded annuities for your retirement savings? Why or why not?

Login or Subscribe to participate in polls.

On Monday, we asked:Ā Do you believe heavy taxation of large landlords is an effective way to discourage institutional ownership of single-family homes?

ā€” Results were split evenly. As for Yes, responses included, ā€œBig companies already have significant tax advantages and access to cheap money. Reducing their profit margin is all that is needed to move their interest to some other part of the economy. ā€

ā€” Another: ā€œLandlords get two significant tax breaks - depreciation and mortgage interest deduction. Removing them would reduce the appeal of single-family homes as rental properties.ā€

ā€” On the other end, readers said, ā€œI am not 100% certain, but I believe that they would probably just absorb the taxes into their costs and increase rents.ā€ Another: ā€œLarge business finds creative ways around taxes. Need to make it illegal to own so many homes.ā€

TRIVIA ANSWER

The modern 401(k) originated in earnest in 1978 with a provision in The Revenue Act of 1978.

See you next time!

That's it for today onĀ We Study Markets!

Enjoy reading this newsletter? Forward it to a friend.

Was this newsletter forwarded to you? Sign upĀ here.

Use the promo code STOCKS15 at checkout for 15% off our popular course ā€œHow To Get Started With Stocks.ā€

Advertise with us.

Follow us on Twitter.

Keep an eye on your inbox for our newsletters on weekdays around 6pm EST and on weekends. If you have any feedback for us, simply respond to this email.

You can also leave your comments/suggestions/feedback anonymouslyĀ here.

What did you think of today's newsletter?

Login or Subscribe to participate in polls.

All the best,

P.S. The Investor's Podcast Network is excited to launch aĀ subredditĀ devoted to our fans in discussing financial markets, stock picks, questions for our hosts, and much more!

Join our subreddit r/TheInvestorsPodcastĀ today!

Ā© The Investor's Podcast Network content is for educational purposes only. The calculators, videos, recommendations, and general investment ideas are not to be actioned with real money. Contact a professional and certified financial advisor before making any financial decisions. No one at The Investor's Podcast Network are professional money managers or financial advisors. The Investorā€™s Podcast Network and parent companies that own The Investorā€™s Podcast Network are not responsible for financial decisions made from using the materials provided in this email or on the website.